Draft MolDX LCDs – Comment Period for the Following Began on April 23, 2020 and Will End on June 6, 2020

The comment period for the following MolDX LCDs began on April 23, 2020 and will end on June 6, 2020:

• Lab: Urine Drug Testing DL38557  
• MolDX: Breast Cancer Index™ (BCI) Gene Expression Test DL37794
• MolDX: EndoPredict Breast Cancer Gene Expression Test DL37264 
• MolDX: Liquid Biopsies for Solid Organ Transplantation DL38568 
• MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells DL38566 
• MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer DL38576 

A link to the proposed billing and coding article is located under the Associated Documents section of the proposed LCD.

• Billing and Coding: Lab: Urine Drug Testing DA58010 
• Billing and Coding: MolDX: Breast Cancer Index™ (BCI) Gene Expression Test DA56875 
• Billing and Coding: MolDX: EndoPredict Breast Cancer Gene Expression Test DA56963 
• Billing and Coding: MolDX: Liquid Biopsies for Solid Organ Transplantation DA58019
• Billing and Coding: MolDX: Phenotypic Biomarker Detection in Circulating Tumor Cells DA58021 
• Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer DA58028 

Source: https://www.palmettogba.com/palmetto/MolDX.nsf/vMasterDID/BNYJ8T7444